ASCO GU 2019 ARCHES trial, metastatic hormone-sensitive prostate cancer (mHSPC), Andrew Armstrong, MD, XTANDI® (enzalutamide) significantly improved radiographic progression-free survival in men with metastatic hormone-sensitive prostate cancer, androgen deprivation therapy with enzalutamide or placebo, ENZA plus ADT, improved rPFS.
— Read on www.urotoday.com/conference-highlights/asco-gu-2019/asco-gu-2019-prostate-cancer/110267-asco-gu-2019-phase-3-study-of-androgen-deprivation-therapy-adt-with-enzalutamide-enza-or-placebo-pbo-in-metastatic-hormone-sensitive-prostate-cancer-mhspc-the-arches-trial.html
A New Minimally Invasive Option for the Treatment of BPH